← Leaderboards
Calvin Proffitt
Leidos Biomedical Research, Inc.
$24,262,802
Attributed
$24,262,802
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $19.4M · FY2022–23$20M$15M$10M$5M$0
'22
'23
Funding mix
By agency
NIH$24,262,802 · 2
By mechanism
N01$24,262,802 · 2
Top collaborators
No co-investigators on record.
Most similar at Leidos Biomedical Research, Inc.
Same institution · by research overlap
- David Heimbrook$2,362,140,846
- Leonard Freedman$1,216,107,431
- Lynn Briscoe$495,968,635
- Ethan Dmitrovsky$597,515,186
- Leonard Freedmand$281,097,701
Others in their field
Other Rising Stars on “Emerging Communicable Diseases”
- Thierry Diagana · University Of Texas Med Br Galveston$37,506,320
- Kevin Saunders · Duke University$18,205,751
- Andrew Tomaras · Forge Therapeutics, Inc.$10,977,909
- M.r.k. (dickon) Alley · An2 Therapeutics, Inc.$9,235,577
- Urs Oschner · Crestone, Inc.$8,499,692
- Amber Mallory · Texas Biomedical Research Institute$8,000,000
Research focus
Emerging Communicable DiseasesFundingServicesCommunicable DiseasesContractorCostData ManagementEbolaWeb SiteClinical Research SiteCollaborationsMeetingsNeeds AssessmentPatient-Focused OutcomesPreparationProtocols DocumentationRecruitResearch SupportSiteTeleconferencesTelephoneTrainingAreaHuman Resources
Grant awards (3)
LEIDOS FUNDING TO59, OPTION 4 SUPPORT RESEARCH LAB AND BIOREPOSITORY IN LIBERIA$10,910,467
N01 · FY2023 · AI · contact PI
LEIDOS FUNDING TO59, OPTION 1 ONE ADDITIONAL SITE IN THE DRC$8,532,380
N01 · FY2023 · AI · contact PI
EMERGING INFECTIOUS DISEASES RESEARCH PREVAIL I, III, V AND PREVAC MALI$4,819,955
N01 · FY2022 · AI · contact PI